Clinical Trial Update: Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections [Phase 3]

View source ↗

Summary

Phase III trial evaluating AB103 for necrotizing soft tissue infections completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fournier Gangrene
• Necrotizing Fasciitis
• Necrotizing Soft-tissue Infections

Drugs mentioned

• AB103

Snippet

Sponsor: Atox Bio Ltd | Conditions: Necrotizing Soft Tissue Infections, Necrotizing Fasciitis | Phase 3 | Status: COMPLETED | Results posted: 2021-10-05